Zynex announces filing of patent for sepsis monitor

Zynex announces filing of patent for sepsis monitor

ENGLEWOOD -- Zynex, Inc. (NASDAQ: ZYXI), announced it has filed for a provisional patent for a noninvasive sepsis monitor. "Sepsis is one of the biggest problems in hospitals today,” said ... Read More

Friday January 15, 2021 0 comments Tags: Englewood, Zynex, Thomas Sandgaard, sepsis monitor

Paragon 28 names Stephen Oesterle to directors board

Paragon 28 names Stephen Oesterle to directors board

ENGLEWOOD -- Paragon 28, Inc. announced Stephen Oesterle has joined the company’s board of directors. "Dr. Oesterle adds extensive experience to our board as both a physician and executive... Read More

Friday January 15, 2021 0 comments Tags: Englewood, Paragon 28, Stephen Oesterle, Albert DaCosta

Zynex announces second utility patent for its blood volume monitor

Zynex announces second utility patent for its blood volume monitor

ENGLEWOOD -- Zynex, Inc . (NASDAQ: ZYXI) reported it has obtained a second U.S. utility patent for its Blood Volume Monitor Device. Thomas Sandgaard , the inventor, has assigned the patent to... Read More

Thursday January 7, 2021 0 comments Tags: Englewood, Zynex, Thomas Sandgaard

Ampio provides update on clinical trials for Ampion treatment of COVID-19

Ampio provides update on clinical trials for Ampion treatment of COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced an update on the launch of a new global clinical trial for intravenous treatment of COVID-19 with Ampion and provided updates... Read More

Tuesday January 5, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, COVID-19

Ampio gets FDA feedback on proposed modifications to special protocol assessment for Ampion

Ampio gets FDA feedback on proposed modifications to special protocol assessment for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced it received guidance from the U.S Food Drug Administration regarding the impact of COVID-19 on its Phase III clinical... Read More

Wednesday December 30, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, FDA

Ampion demonstrates safety in COVID patients and initiates global trial for intravenous Ampion

Ampion demonstrates safety in COVID patients and initiates global trial for intravenous Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it hascompleted its Phase I clinical trial and has initiated the first steps for a global Phase II clinical trial for... Read More

Friday December 18, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, COVID-19, Ampion

Ampio enters into collaborative research agreements to explore additional clinical indications for Ampion

Ampio enters into collaborative research agreements to explore additional clinical indications for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug,... Read More

Monday December 14, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, FDA, COVID-19

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

Ampio's Phase I study for inhaled Ampion advances to completing enrollment of COVID-19 patients

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following... Read More

Friday December 4, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, COVID-19, Inhaled Ampion